Scarica l'app Stockscreener
0.1799
11.20%
-0.0227
Dopo l'orario di chiusura:
.18
0.000100
+0.06%
Precedente Chiudi:
$0.2026
Aprire:
$0.192
Volume 24 ore:
1.41M
Relative Volume:
0.95
Capitalizzazione di mercato:
$17.57M
Reddito:
$27.47M
Utile/perdita netta:
$-26.60M
Rapporto P/E:
-0.574
EPS:
-0.3134
Flusso di cassa netto:
$-21.86M
1 W Prestazione:
-28.30%
1M Prestazione:
-36.27%
6M Prestazione:
-74.97%
1 anno Prestazione:
-77.23%
Intervallo 1D:
$0.174
$0.20
Intervallo di 1 settimana:
$0.174
$0.2417
Portata 52W:
$0.174
$1.03
Cue Biopharma Inc Stock (CUE) Company Profile
Nome
Cue Biopharma Inc
Settore
Industria
Telefono
617-949-2680
Indirizzo
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.1799 | 17.57M | 27.47M | -26.60M | -21.86M | -0.3134 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-13 | Iniziato | Jefferies | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2022-11-21 | Iniziato | Piper Sandler | Overweight |
| 2022-01-13 | Iniziato | H.C. Wainwright | Buy |
| 2022-01-03 | Iniziato | Craig Hallum | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-04-09 | Iniziato | Stifel | Buy |
| 2020-01-28 | Iniziato | BTIG Research | Buy |
| 2020-01-22 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Cue Biopharma Inc Borsa (CUE) Ultime notizie
CUE Should I Buy - Intellectia AI
CUE.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
CUE.O PE Ratio & Valuation, Is CUE.O Overvalued - Intellectia AI
CUE News & Events - Intellectia AI
CUE.O Forecast — Price Prediction for 2026. Should I Buy CUE.O? - Intellectia AI
CUE.O Technical Analysis & Stock Price Forecast - Intellectia AI
[EFFECT] Cue Biopharma, Inc. SEC Filing - Stock Titan
IPO Launch: Is Cue Biopharma Inc benefiting from interest rate changesWeekly Market Summary & Free Community Supported Trade Ideas - baoquankhu1.vn
Cue Biopharma names Lucinda Warren interim CEO By Investing.com - Investing.com Canada
CUE stock slips as CEO leaves after just six months in role - MSN
Cue Biopharma CEO Resignation Leads to 8% Stock Drop - Intellectia AI
Cue Biopharma Appoints CFO Dr. Kerri-Ann Millar as Interim CEO Following Daniel Passeri’s Departure - geneonline.com
Cue Biopharma Names Lucinda Warren Interim Chief Executive - TipRanks
Cue Biopharma names Lucinda Warren interim CEO - Investing.com
Cue Biopharma IncLucinda Warren to continue as chief financial and business officerSEC filing - marketscreener.com
Cue Biopharma Appoints Lucinda Warren as Interim President and CEO Following Leadership Transition - Quiver Quantitative
Cue Biopharma Announces CEO Transition - weeklyvoice.com
Leadership shift at Cue Biopharma (NASDAQ: CUE) as Warren steps up - Stock Titan
Movement Recap: Is Cue Biopharma Inc forming a bullish divergence2026 Action & High Conviction Investment Ideas - baoquankhu1.vn
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026 - Bluefield Daily Telegraph
Autoimmune drug CUE-401 to headline Cue Biopharma virtual event - Stock Titan
Cue Biopharma Inc stock faces key test amid biotech volatility and pipeline progress - AD HOC NEWS
Cue Biopharma (CUE) Projected to Post Earnings on Monday - Defense World
If You Invested $1,000 in Cue Biopharma Inc (CUE) - Stock Titan
Published on: 2026-03-21 13:01:47 - baoquankhu1.vn
Buyout Rumor: What chart patterns are forming on Cue Biopharma IncShare Buyback & Community Consensus Picks - baoquankhu1.vn
Certain Stock Incentive Plan of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 20-MAR-2026. - marketscreener.com
Certain Common Stock of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 20-MAR-2026. - MarketScreener
Certain Options of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 20-MAR-2026. - marketscreener.com
Loss Report: Can Cue Biopharma Inc outperform in the next rallyIndex Update & Verified Momentum Stock Alerts - baoquankhu1.vn
Cue Biopharma (NASDAQ: CUE) files $300M shelf registration, $12.7M ATM via Jefferies - Stock Titan
Cue Biopharma 2024 Annual Report – Clinical-Stage Immunotherapy Pipeline, Regulatory Strategy, and Collaboration Highlights - Minichart
CUE SEC FilingsCue Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Stock Report: Whats the RSI of Cue Biopharma Inc stockEarnings Growth Report & Smart Money Movement Alerts - baoquankhu1.vn
Cue Biopharma earnings beat by $0.10, revenue topped estimates - Investing.com Canada
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Bitget
Cue Biopharma issues quarterly and annual earnings update - Traders Union
Cue Biopharma : Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - marketscreener.com
Reverse split on agenda as Cue Biopharma (CUE) plans 2026 virtual meeting - Stock Titan
Cue Biopharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Cue Biopharma (CUE) posts 2025 results and $15M ImmunoScape pact - Stock Titan
Cue Biopharma (CUE) pivots to autoimmune focus amid going concern risk - Stock Titan
Cue Biopharma, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Cue Biopharma (CUE) price target decreased by 20.00% to 4.08 - MSN
Published on: 2026-03-13 09:51:08 - baoquankhu1.vn
Cue Biopharma (CUE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Cue Biopharma to present new in vitro data for CUE-401 - TipRanks
Cue Biopharma (CUE) Unveils Promising CUE-401 Data at Global Con - GuruFocus
Cue Biopharma unveils in vitro data for CUE-401 in autoimmune disease research - Traders Union
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 - The Manila Times
CUE-401 lab data hint at rebalancing immune attacks in autoimmune disease - Stock Titan
Cue Biopharma Inc Azioni (CUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):